Xuanwu Hospital Beijing, Capital Medical University
Beijing, Beijing Municipality, 100053, China
NCT Number: NCT04973020
The study is a single-center, open, single-dose, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects.Subjects will take the SHR6390 on Day1 and Day22 , and from Day8 to Day26 take the efavirenz.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Beijing, Beijing Municipality, 100053, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SHR6390 tablet single dose;Efavirenz single dose.
Time frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
Time to maximum observed serum concentration (Tmax) for SHR6390 after Single dose.
Time frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
Maximum observed serum concentration (Cmax)for SHR6390 after Single dose.
Time frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
Area under the plasma concentration versus time curve (AUC0-t) for SHR6390 after Single dose.
Time frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
Area under the plasma concentration versus time curve (AUC0-inf ) for SHR6390 after Single dose.
Time frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
Time to elimination half-life (T1/2) for for SHR6390 after Single dose.
Time frame: from Day 1 to Day 34 after the first dose
Jiangsu HengRui Medicine Co., Ltd.
Industry
A Single-centre, Single-dose, Open-label and Self-control Study to Evaluate the Effect of Efavirenz on Pharmacokinetic of SHR6390 in Healthy Chinese Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04374877
Adenocarcinoma, Advanced Solid Tumor
Duarte, California, United States
View Trial DetailsNCT06470763
Advanced Solid Tumor
Detroit, Michigan, United States
View Trial DetailsNCT06403436
Adult Disease, Adult Solid Tumor
Nashville, Tennessee, United States
View Trial DetailsNCT03239145
Adnexal Diseases, Advanced Solid Tumor
Boston, Massachusetts, United States
View Trial Details